Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.
Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.